FOR IMMEDIATE RELEASE
Senior Policy Analyst
Cascade Policy Institute
Phone: (503) 242-0900
February 21, 2012
Requiring a Prescription for Cold Medicine Has Not Reduced Meth Use in Oregon
Cascade Study Raises Questions about Real Impact of Oregon’s
PORTLAND, OR — Cascade Policy Institute released a study today which found the 2005 Oregon law which restricts access to medicines containing pseudoephedrine (PSE) has not made the illegal drug methamphetamine harder to get or reduced the number of people using it. The Oregon law makes any medication containing PSE available only via prescription (“Rx-only”).
“This study affirms what we predicted over six years ago: The law would not significantly curb meth use or production, but it would impose a considerable burden on legitimate users of cold and allergy medicines like Claritin-D and Sudafed,” said Steve Buckstein, Cascade’s founder and Senior Policy Analyst. “With other state and federal lawmakers considering following Oregon’s lead on this issue, we thought it was critical to find out what has actually happened here since the law went into effect.”
“The prescription requirement for cold and allergy medicines containing pseudoephedrine had no more of an impact on the reduction of meth lab incidents than other measures adopted in neighboring states. In fact, the rate of mobile meth lab reductions in Oregon is nearly identical to that of six neighboring and nearby states that do not have a prescription requirement. Moreover, meth addicts in Oregon can still get access to their drug of choice,” added Buckstein. “Overall, our study raises fundamental questions about the effectiveness of Oregon’s law and whether such a prescription mandate—which impacts all consumers in the state—is warranted.”
Key findings of the study:
- Law enforcement in Oregon report that methamphetamine remains the state’s greatest drug threat, despite the reduction in in-state meth production, and contributes the most towards drug-related crime.
- Methamphetamine lab incidents in Oregon declined more than 90 percent between 2004 and 2010. Most of this decline occurred before the prescription-only law went into effect in 2006.
- Six neighboring states including Washington and California experienced similar declines in meth lab reductions without imposing a prescription requirement during the same time frame.
- The number of methamphetamine admissions to substance abuse centers in Oregon declined about 23 percent from 2006 to 2009, the exact same rate as the rest of the United States. Usage was slightly higher in California at 29 percent and slightly lower in Washington at 20 percent.
- Legitimate users of pseudoephedrine in Oregon incur additional costs as a result of this law, because it requires a doctor visit to get Sudafed and similar products that are available over-the-counter in 48 other states. Some of these additional costs are also borne by all taxpayers who fund government health care programs.
The first part of the study examines whether the manufacture and availability of methamphetamine in Oregon is substantially different from similar states and similar regions of the country. Part two examines trends in indicators that track methamphetamine production, such as Oregon’s lab incidents compared to other states. Part three examines trends in indicators of methamphetamine use, such as substance abuse-related admissions in Oregon compared to other geographies. And finally, part four explores the costs, financial and otherwise, to consumers.
The report’s findings are consistent with studies conducted by other independent groups, such as Oregon’s High Intensity Drug Area (HIDTA), which reported: “Methamphetamine continues to be highly available and widely used throughout the HIDTA region and remains the most serious drug threat to Oregon” (“Threat Assessment & Counter-Drug Strategy,” 2011 Oregon High Intensity Drug Trafficking Areas (HIDTA) Report, Accessed 9/26/11).
Please visit the Cascade Policy Institute website to read the entire study, entitled
The study was conducted by Chris Stomberg, Ph.D., a Partner, and Arun Sharma, a Principal, in the Antitrust and Competition, and Healthcare practices at Bates White, LLC, an economic consulting firm based in Washington, D.C. Primary report author Chris Stomberg can be contacted at firstname.lastname@example.org or (202) 747-1421.